Purgo Scientific

Purgo Scientific is a private, preclinical-stage biotech company based in San Diego, founded in 2018. The company is developing the Purgo Pouch, a combination product device designed for localized, sustained antibiotic delivery to treat orthopedic biofilm infections, with an initial target indication of fracture-related infections. With clinical testing planned for 2027 and a foundation of preclinical data from over 140 sheep, the company is addressing a significant unmet need in surgical site infections, which cost the U.S. healthcare system $10 billion annually. Purgo Scientific is positioned in the high-stakes medical device and localized therapeutic delivery market within orthopedics.

Localized sustained drug delivery device (Purgo Pouch) designed to deliver antibiotics directly to surgical sites to combat biofilm infections.

Competition includes established antibiotic-loaded bone cements (PMMA), absorbable antibiotic beads, and collagen sponges. Newer technologies and companies are also developing advanced local delivery systems. Purgo aims to differentiate through a sustained release profile and specific efficacy against resilient biofilms, a claim it must prove clinically.